If you made any changes in Pure, your changes will be visible here soon.

Personal profile


Thomas Yankeelov serves as Director of Cancer Imaging Research in the LIVESTRONG Cancer Institutes of the Dell Medical School. He holds the W.A. "Tex" Moncrief Jr., Simulation-Based Engineering and Sciences Professorship in Computational Oncology and leads the Tumor Modeling Group in the university's Institute for Computational Engineering and Sciences.

He is a computational biomedical engineer and came to The University of Texas at Austin from Vanderbilt University, where he served as the Ingram Professor of Cancer Research; professor of radiology and radiological sciences, physics, biomedical engineering and cancer biology; and director of cancer imaging research. He also served as a co-leader of the Host-Tumor Interactions Research Program for the Vanderbilt-Ingram Cancer Center.

Yankeelov is the recipient of a distinguished $6 million recruitment grant from the Cancer Prevention and Research Institute of Texas (CPRIT).

His clinical research focuses on improving patient care by employing advanced imaging methods for the early identification, assessment and prediction of tumors and their response to therapy. He has developed successful tumor-forecasting methods by combining imaging technologies with patient-specific data to build predictive, multiscale biophysical models of tumor growth. His research emphasizes the importance of offering personalized therapies to cancer patients.

Yankeelov is a fellow of the American Institute of Medical and Biological Engineers and has served on the editorial boards of scientific publications such as Magnetic Resonance Imaging, Medical Physics and Breast Cancer Research. He received his B.A. in mathematics from the University of Louisville, his M.A. in applied mathematics and M.S. in physics, both from Indiana University, and his Ph.D. in biomedical engineering from Stony Brook University.

Fingerprint Fingerprint is based on mining the text of the experts' scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.

  • 5 Similar Profiles
Breast Neoplasms Medicine & Life Sciences
Magnetic Resonance Imaging Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Tumors Engineering & Materials Science
Magnetic resonance Engineering & Materials Science
Diffusion Magnetic Resonance Imaging Medicine & Life Sciences
Breast Medicine & Life Sciences
Imaging techniques Engineering & Materials Science

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 2003 2018

6 Citations

Accuracy, repeatability, and interplatform reproducibility of T1 quantification methods used for DCE-MRI: Results from a multicenter phantom study

Bane, O., Hectors, S. J., Wagner, M., Arlinghaus, L. L., Aryal, M. P., Cao, Y., Chenevert, T. L., Fennessy, F., Huang, W., Hylton, N. M., Kalpathy-Cramer, J., Keenan, K. E., Malyarenko, D. I., Mulkern, R. V., Newitt, D. C., Russek, S. E., Stupic, K. F., Tudorica, A., Wilmes, L. J., Yankeelov, T. & 3 othersYen, Y. F., Boss, M. A. & Taouli, B., May 1 2018, In : Magnetic Resonance in Medicine. 79, 5, p. 2564-2575 12 p.

Research output: Contribution to journalArticle

Multicenter Studies
Linear Models
In Vitro Techniques
2 Citations

A hybrid three-scale model of tumor growth

Rocha, H. L., Almeida, R. C., Lima, E. A. B. F., Resende, A. C. M., Oden, J. T. & Yankeelov, T., Jan 1 2018, In : Mathematical Models and Methods in Applied Sciences. 28, 1, p. 61-93 33 p.

Research output: Contribution to journalArticle

Tumor Growth
2 Citations

Biophysical Modeling of In Vivo Glioma Response After Whole-Brain Radiation Therapy in a Murine Model of Brain Cancer

Hormuth, D. A., Weis, J. A., Barnes, S. L., Miga, M. I., Quaranta, V. & Yankeelov, T., Apr 1 2018, In : International Journal of Radiation Oncology Biology Physics. 100, 5, p. 1270-1279 10 p.

Research output: Contribution to journalArticle

Brain Neoplasms
radiation therapy
Magnetic Resonance Imaging
Breast Neoplasms
Area Under Curve

Dual Src and EGFR inhibition in combination with gemcitabine in advanced pancreatic cancer: phase I results: A phase I clinical trial

Cardin, D. B., Goff, L. W., Chan, E., Whisenant, J. G., Dan Ayers, G., Takebe, N., Arlinghaus, L. R., Yankeelov, T., Berlin, J. & Merchant, N., Jun 1 2018, In : Investigational New Drugs. 36, 3, p. 442-450 9 p.

Research output: Contribution to journalArticle

Clinical Trials, Phase I
Pancreatic Neoplasms
Maximum Tolerated Dose